General AML

ESH 2019 | What is the risk of developing AML in women previously treated for breast cancer?

L:

The AML Global Portal were delighted to speak to Norbert Vey, Institut Paoli-Calmettes, Marseille, FR, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Norbert Vey: What is the risk of developing AML in women previously treated for breast cancer? In this video, he discusses haematological malignancy findings from a French nationwide database of 450,000 women with breast cancer over the years 2009-2016.

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF
Was this article informative? Thank you for your feedback!
100% of people found this article informative